AI
ACRS icon

Atom Investors’s Aclaris Therapeutics ACRS Stock Holding History

Atom Investors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$787K Buy
+148,855
New +$664K 0.07% 425
2023
Q4 		– Sell
-22,343
Closed -$153K – 441
2023
Q3 		$153K Buy
+22,343
New +$191K 0.03% 392
2021
Q4 		– Sell
-25,197
Closed -$454K – 264
2021
Q3 		$454K Sell
25,197
-157,393
-86% -$2.52M 0.04% 208
2021
Q2 		$3.21M Buy
+182,590
New +$4.15M 0.4% 40

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Atom Investors's ACRS Position: Q2 2026 in Review

Atom Investors opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 148,855 shares worth $787K. The stake represents 0.07% of the portfolio and ranks #425 among its holdings. This is a return to the name: Atom Investors previously reported a position in ACRS as recently as Q3 2023.

Atom Investors first reported a position in ACRS in Q2 2021 and has held it in 4 quarters since. The position peaked at $3.21M in Q2 2021. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Atom Investors held 148,855 shares of Aclaris Therapeutics worth $787K as of Q2 2026.
  • Aclaris Therapeutics was a new Atom Investors position in Q2 2026.
  • Aclaris Therapeutics made up 0.07% of Atom Investors's portfolio in Q2 2026, its #425 holding.
  • Atom Investors first reported a position in Aclaris Therapeutics in Q2 2021 and has held it in 4 quarters since.
  • Atom Investors's Aclaris Therapeutics position peaked at $3.21M in Q2 2021.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.